An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Clinical trial NCT06281847 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06281847
Sponsor: Advesya SAS
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia, in Relapse Acute Myeloid Leukemia Refractory

Start date: 2025-12-01
Primary completion: 2027-07-01
Enrollment: 143

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.